QSAR model for *In vitro* gene mutation study in bacteria (Ames test) (v1.0)



GenoITS

GenoITS is a computational workflow focused on the prediction of genotoxicity using the Integrated Testing Strategy proposed by REACH. GenoITS uses 5 different QSAR models to perform the complete workflow, one per each kind of study demanded by REACH (gene mutation in bacteria; *in vitro* cytogenicity; *in vitro* gene mutation; *in vivo* cytogenicity; *in vivo* gene mutation). ProtoITS also allows the users to supply their own experimental data.

GenoITS was developed as a part of the GenoQSAR research project. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101030422.

Endpoint

Human health effects: Mutagenicity. OECD 471: Bacterial reverse mutation test.

Mutagenicity refers to the induction of permanent transmissible changes in the amount or structure of the genetic material of cells or organisms. The Bacterial reverse mutation test evaluates gene mutations. The test uses amino-acid requiring strains of bacteria to detect (reverse) gene mutations (point mutations and frameshifts).

Parameters

Metrics

Training set

Experimental values	QSAR predictions		
	non-mutagenic	mutagenic	
non-mutagenic	2048	203	
mutagenic	154	2463	

Accuracy	0.93	0.76
Sensitivity / recall	0.94	0.78
Specificity	0.91	0.74
Precision	0.92	0.78
Negative predictive value	0.93	0.74
F-score	0.93	0.78
Matthews Correlation Coefficient	0.85	0.52
Critical Success Index	0.87	0.64
Area under the ROC	0.93	0.76

Training

Validation set

Experimental values	QSAR predictions		
	non-mutagenic	mutagenic	
non-mutagenic	553	196	
mutagenic	190	685	

GenoITS is part of



ProtoPRED platform allows the easy, fast and user-friendly prediction of different properties of chemical compounds, by proprietary (Q)SAR models.



+34 962 021 811



protopred@protoqsar.com

Validation